What All These Injuries Have in Common Shared Characteristics: Underreported in clinical trials The true incidence emerged only after millions of prescriptions Downplayed by manufacturers Described as rare or temporary when they may be common and permanent Life-altering severity These arent minor side effects
Sources New England Journal of Medicine, STEP 1 trial of semaglutide 2.4 mg (2021): New England Journal of Medicine, SURMOUNT-1 trial of tirzepatide (2022): New England Journal of Medicine, SURMOUNT-5 head-to-head trial (2025): Saxenda (liraglutide) prescribing information and SCALE trial data: See your options in about 2 minutes Take the free quiz and see what fits you
CJC-1295 + Ipamorelin Increases natural growth hormone release to support fat loss, muscle gain, and recovery
10.1007/s12602-023-10079-1 64 HiguchiA
In January, Independence Blue Cross, the areas largest insurer, stopped covering any weight loss drugs when they are prescribed solely to lose weight, citing high costs
The receptor profiles are different (dual versus triple agonist), the potency per milligram is different, and the side effect profiles are different
